HC Wainwright Issues Positive Outlook for TNGX Earnings

Tango Therapeutics, Inc. (NASDAQ:TNGX) – Analysts at HC Wainwright raised their Q3 2026 EPS estimates for Tango Therapeutics in a research report issued to clients and investors on Tuesday, June 9th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings of ($0.26) per share for the quarter, up from their previous forecast of ($0.31). HC Wainwright currently has a “Buy” rating and a $66.00 price objective on the stock. The consensus estimate for Tango Therapeutics’ current full-year earnings is ($1.29) per share. HC Wainwright also issued estimates for Tango Therapeutics’ Q4 2026 earnings at ($0.27) EPS and FY2026 earnings at ($1.15) EPS.

Tango Therapeutics (NASDAQ:TNGX) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.32) EPS for the quarter, meeting the consensus estimate of ($0.32). Tango Therapeutics had a negative net margin of 151.15% and a negative return on equity of 41.54%.

Several other equities analysts also recently commented on TNGX. Weiss Ratings downgraded shares of Tango Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, May 28th. Jefferies Financial Group cut shares of Tango Therapeutics from a “buy” rating to a “hold” rating and boosted their target price for the company from $18.00 to $27.00 in a research report on Thursday, May 14th. Wedbush boosted their target price on shares of Tango Therapeutics from $19.00 to $33.00 and gave the company an “outperform” rating in a research report on Thursday, May 14th. Guggenheim boosted their target price on shares of Tango Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Friday, March 6th. Finally, Leerink Partners boosted their target price on shares of Tango Therapeutics from $55.00 to $69.00 and gave the company an “outperform” rating in a research report on Monday. Eleven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $38.42.

Tango Therapeutics Price Performance

NASDAQ:TNGX opened at $28.68 on Thursday. Tango Therapeutics has a one year low of $4.32 and a one year high of $32.79. The company has a market cap of $4.15 billion, a P/E ratio of -34.55 and a beta of 1.19. The firm’s fifty day moving average price is $23.09 and its two-hundred day moving average price is $16.13.

Institutional Investors Weigh In On Tango Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Adage Capital Partners GP L.L.C. lifted its position in Tango Therapeutics by 322.5% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 10,607,924 shares of the company’s stock worth $93,986,000 after purchasing an additional 8,096,924 shares during the period. Caligan Partners LP bought a new stake in Tango Therapeutics during the fourth quarter worth about $33,047,000. Goldman Sachs Group Inc. lifted its position in Tango Therapeutics by 227.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 4,942,414 shares of the company’s stock worth $43,790,000 after purchasing an additional 3,432,939 shares during the period. Logos Global Management LP lifted its position in Tango Therapeutics by 342.1% during the fourth quarter. Logos Global Management LP now owns 4,200,000 shares of the company’s stock worth $37,212,000 after purchasing an additional 3,250,000 shares during the period. Finally, Paradigm Biocapital Advisors LP bought a new stake in Tango Therapeutics during the third quarter worth about $25,924,000. Institutional investors own 78.99% of the company’s stock.

Insider Activity

In other news, insider Adam Crystal sold 27,000 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $22.87, for a total value of $617,490.00. Following the completion of the sale, the insider owned 115,743 shares of the company’s stock, valued at approximately $2,647,042.41. The trade was a 18.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have sold a total of 131,460 shares of company stock valued at $2,965,920 over the last three months. Insiders own 6.50% of the company’s stock.

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.